A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids.

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Lebrikizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms MILLY
  • Sponsors Genentech
  • Most Recent Events

    • 18 May 2016 Results (pooled analysis of this and other two studies) assessing correlation between the change in these pharmacodynamics biomarkers and the change in FEV1 presented at the 112th International Conference of the American Thoracic Society.
    • 18 May 2016 Results of pooled analysis of three phase II studies including this study presented at the 112th International Conference of the American Thoracic Society
    • 07 Mar 2016 Results (post hoc pooled analysis of this and other two studies (n = 659) assessing prevalence of key Type 2 biomarkers) presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top